• Imbruvica, Rituxan Combination sNDA Accepted for Review by FDA americanpharmaceuticalreview
    June 27, 2018
    AbbVie announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review a supplemental New Drug Application (sNDA) for Imbruvica (ibrutinib) in combination with rituximab (Rituxan) as a new treatment option for Waldenström's macroglo
PharmaSources Customer Service